News | June 23, 2026
Teva closes $700M Emalex acquisition
Bolstering neuroscience push with late-stage Tourette therapy
Bolstering neuroscience push with late-stage Tourette therapy
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
The collaboration is focused on overcoming a major limitation in existing cancer drugs
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Seasoned pharmaceutical R&D leader takes on an expanded leadership role to drive innovation and strengthen Hetero’s advanced formulation development capabilities
Study will assess the safety and effectiveness of irreversible electroporation as a minimally invasive treatment option for benign prostatic hyperplasia (BPH)
Subscribe To Our Newsletter & Stay Updated
